ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Immunopharmacological and structural design of a polyprotein based multi epitope vaccine against Powassan virus.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Powassan virus (POWV) poses a growing neurotropic threat with limited immunopharmacological interventions, requiring the development of targeted vaccine strategies. The current study focuses on developing a specific vaccine using bioinformatics tools to target T- and B-cell epitopes from a genome polyprotein sequence of POWV. Four vaccine constructs with possible immunogenic qualities were assembled. Two specific epitopes were selected from B-cell, and T-cell for each construct. The heat-labile enterotoxin S63 adjuvant was attached to the N-terminal, while the PADRE order and the His-tag were added to the C-terminal with appropriate linkers. The vaccine constructs showed 62%, 80%, 90%, and 72% of average global population coverage. The Ramachandran scores were observed to be ≥ 90%, and the instability index was 35.13, validating stable structures. Docking analysis showed strong affinity for V1-TLR7 (-1380), V2-TLR7 (-1615.7), V2-TLR8 (-1033.8), V3-TLR7 (-1692.7), V3-TLR8 (-1097.6), ACE (-1127.2), V4-TLR7 (-1689.4), and V4-TLR10 (-1240.8 kcal/mol) complexes, respectively. However, molecular dynamics simulations revealed a consistent interaction pattern for the complex TLR8-construct3. The vaccine constructs ligated into the pBR322 vector showed successful insertion and expression. A strong immune response was observed, with elevated IgM + IgG concentrations within 10 days of injection, which normalized by 30-35 days. In conclusion, the current research highlights the possibility of an innovative vaccine against the virus. To extend our efforts and bridge the gap between vaccine design and reducing the burden of POWV, further in vitro and in in vivo studies are necessary.
Indexed as
Identifiers
42287315What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.